NCT01010646 - Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

November 30, 2013

Conditions

Chronic Hepatitis C

Interventions

DRUG

IFN alfa-2b XL 27 MUI + Ribavirin

IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses

DRUG

IFN alfa-2b XL 36 MUI + Ribavirin

IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses

DRUG

IFN peg alfa-2b 1.5 µg/kg + Ribavirin

IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses

Trial Locations (1)

69004

Hôpital de la Croix Rousse, Lyon